Advertisement
Australia markets open in 7 hours 26 minutes

  • ALL ORDS

    7,937.90
    +35.90 (+0.45%)
     

  • AUD/USD

    0.6486
    +0.0035 (+0.54%)
     

  • ASX 200

    7,683.50
    +34.30 (+0.45%)
     

  • OIL

    82.98
    +1.08 (+1.32%)
     

  • GOLD

    2,338.90
    -7.50 (-0.32%)
     

  • Bitcoin AUD

    102,757.41
    +734.94 (+0.72%)
     

  • CMC Crypto 200

    1,436.23
    +21.47 (+1.52%)
     

Bellerophon to Present at the H.C. Wainwright Global Life Sciences Conference

Bellerophon Therapeutics, Inc.
·1-min read

WARREN, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

The presentation will be available on-demand beginning on Tuesday, March 9, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

At W2O Group:

At LifeSci Advisors:

Julie Normart

Brian Ritchie

(559) 974-3245

(212) 915-2578

jnormart@w2ogroup.com

britchie@lifesciadvisors.com